Population pharmacokinetic-pharmacodynamic modelling in oncology: A tool for predicting clinical response

British Journal of Clinical Pharmacology

Volumn 79, Issue 1, 2015, Pages 56-71

  Bender, Brendan C ^a   Schindler, Emilie ^a   Friberg, Lena E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

biomarkers; oncology; PKPD; population modelling; time to event; tumour

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER; PHARMACOLOGICAL BIOMARKER;

ADVERSE DRUG REACTION; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; ELEVATED BLOOD PRESSURE; FEEDBACK SYSTEM; HUMAN; HYPERTRANSAMINASEMIA; ONCOLOGY; OVERALL SURVIVAL; PARAMETRIC TEST; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; STEADY STATE; TUMOR GROWTH; TUMOR VOLUME; BIOLOGICAL MODEL; COMPUTER SIMULATION; NEOPLASMS; TIME FACTOR;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BIOMARKERS, TUMOR; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; TIME FACTORS;

EID: 84988905874     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12258     Document Type: Article

References (73)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Kummar S, Gutierrez M, Doroshow JH, Murgo AJ,. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006; 62: 15-26.
3. FDA. Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2007. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (last accessed 7 November 2013).
4. Booth CM, Eisenhauer EA,. Progression-free survival: meaningful or simply measurable? J Clin Oncol 2012; 30: 1030-1033.
5. Bruno R, Claret L,. On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther 2009; 86: 136-138.
6. Mould DR, Upton RN,. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2013; 2: e38.
7. Joerger M,. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J 2012; 14: 119-132.
8. Della Pasqua O,. PKPD and disease modeling: concepts and applications to oncology. In: Clinical Trial Simulations: Applications and Trends, eds, Kimko HHC, Peck CC,. New York: Springer, 2011; 281-310.
9. Wright DF, Winter HR, Duffull SB,. Understanding the time course of pharmacological effect: a PKPD approach. Br J Clin Pharmacol 2011; 71: 815-823.
10. Karlsson MO, Anehall T, Friberg LE, Henningsson A, Kloft C, Sandstrom M, Xie R,. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. Basic Clin Pharmacol Toxicol 2005; 96: 206-211.
11. Duffull SB, Wright DF, Winter HR,. Interpreting population pharmacokinetic-pharmacodynamic analyses-a clinical viewpoint. Br J Clin Pharmacol 2011; 71: 807-814.
12. Keizer RJ, Schellens JH, Beijnen JH, Huitema AD,. Pharmacodynamic biomarkers in model-based drug development in oncology. Curr Clin Pharmacol 2011; 6: 30-40.
13. Mould DR,. Models for disease progression: new approaches and uses. Clin Pharmacol Ther 2012; 92: 125-131.
14. Mould DR, Upton RN,. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 2012; 1: e6.
15. Bruno R, Mercier F, Claret L,. Model-based drug development in oncology: what's next? Clin Pharmacol Ther 2013; 93: 303-305.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J,. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
17. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen GA,. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-338.
18. Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, Goh BC, Holford NHG,. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 4213-4218.
19. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J,. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009; 86: 167-174.
20. Claret L, Lu JF, Bruno R, Hsu CP, Hei YJ, Sun YN,. Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer. Clin Pharmacol Ther 2012; 92: 631-634.
21. Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR,. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther 2013; 93: 345-351.
22. Stein A, Wang W, Carter AA, Chiparus O, Hollaender N, Kim H, Motzer RJ, Sarr C,. Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. BMC Cancer 2012; 12: 311.
23. Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R,. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009; 27: 4103-4108.
24. Hansson EK, Westwood P, Amantea M, French J, Houk B, Milligan PA, Karlsson MO, Friberg LE,. Pharmacokinetic-Pharmacodynamic modeling of VEGF, sVEGFR-2, sVEGFR-3 and sKIT as biomarkers of tumor response and overall survival following sunitinib treatment in GIST. CPT Pharmacomet Syst Pharmacol 2013; 2: e84.
25. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ,. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66: 357-371.
26. Lu JF, Claret L, Sutjandra L, Kuchimanchi M, Melara R, Bruno R Sun YN,. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemother Pharmacol 2010; 66: 1151-1158.
27. Claret L, Gupta M, Joshi A, Sarapa N, He J, Powell B, Bruno R,. Evaluation of tumor-size response metrics to predict survival and progression free survival in first-line metastatic colorectal cancer. Annual Meeting of the Population Approach Group in Europe (PAGE). June 5, 2012; Venice, Italy.
28. Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R,. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol 2013; 31: 2110-2114.
29. Hansson EK,. Pharmacometric Models for Biomarkers, Side Effects and Efficacy in Anticancer Drug Therapy. Uppsala: Acta Universitatis Upsaliensis, 2012.
30. Frances N, Claret L, Bruno R, Iliadis A,. Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer Chemother Pharmacol 2011; 68: 1413-1419.
31. Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY, Honnorat J, Grenier E, Ducray F,. A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res 2012; 18: 5071-5080.
32. Bruno R, Lindbom. L, Schaedeli SF, Chanu P, Gilberg F, Frey N, Claret L, Simulations to assess phase II noninferiority trials of different doses of capecitabine in combination with docetaxel for metastatic breast cancer. CPT: Pharmacometrics Syst Pharmacol 2012; 1: e19.
33. Bonate PL, Suttle B,. Effect of censoring due to progressive disease on tumor size kinetic parameter estimates. AAPS J 2013; 15: 832-839.
34. Friberg LE, de Greef R, Kerbusch T, Karlsson MO,. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 2009; 86: 84-91.
35. Korn RL, Crowley JJ,. Overview: progression-free survival as an endpoint in clinical trials with solid tumors. Clin Cancer Res 2013; 19: 2607-2612.
36. You B, Girard P, Paparel P, Freyer G, Ruffion A, Charrie A, Henin E, Tod M, Perrin P,. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy. Prostate 2009; 69: 1325-1333.
37. You B, Fronton L, Boyle H, Droz JP, Girard P, Tranchand B, Ribba B, Tod M, Chabaud S, Coquelin H, Flechon A,. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor. Urology 2010; 76: 423-429 e2.
38. Jonsson F, Claret L, Knight R, Olesnyckyj M, Jacques C, Rajkumar VS, Bruno R,. A longitudinal tumor growth inhibition model based on serum M-protein levels in patients with multiples myeloma treated by dexamethasone. Annual Meeting of the Population Approach Group in Europe (PAGE). June 8, 2010; Berlin, Germany.
39. Wilbaux M, You B, Hénin E, Colomban O, Freyer G, Tod M,. Population K-PD joint modeling of tumor size and CA 125 kinetics after chemotherapy in relapsed ovarian cancer (ROC) patients. Annual Meeting of the Population Approach Group in Europe (PAGE). June 5, 2012; Venice, Italy.
40. Sharma A, Jusko WJ,. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 1998; 45: 229-239.
41. Post TM, Freijer JI, DeJongh J, Danhof M,. Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 2005; 22: 1038-1049.
42. Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, Dodos F, Sorgel F, Fuhr U, Jaehde U,. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther 2010; 87: 601-608.
43. Mager DE, Jusko WJ,. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 2001; 70: 210-216.
44. Kanefendt F, Lindauer A, Kinzig M, Scheulen M, Strumberg D, Fischer R, Sorgel F, Mross K, Jaehde U,. Modeling sunitinib and biomarker response as potential predictors of time to progression in patients with metastatic colorectal cancer. Annual Meeting of the Population Approach Group in Europe (PAGE). June 5, 2012; Venice, Italy.
45. Hansson EK, Ma HG, Amantea M, French J, Milligan PA, Friberg LE, Karlsson MO,. PKPD modeling of predictors for side effects and overall survival in sunitinib treated patients with gastrointestinal stromal tumor. CPT Pharmacometrics Syst Pharmacol 2013; 2: e85.
46. Schindler E, Westwood P, Amantea M, Hansson EK, Milligan PA, Karlsson MO, Friberg LE,. PKPD-modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib. Annual Meeting of the Population Approach Group in Europe (PAGE). June 5, 2012; Venice, Italy.
47. Keizer RJ, Funahashi Y, Semba T, Wanders J, Beijnen JH, Schellens JH, Huitema ADR,. Evaluation of alpha2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. AAPS J 2011; 13: 230-239.
48. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO,. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-4721.
49. Hansson EK, Friberg LE,. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemother Pharmacol 2012; 69: 881-890.
50. van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema ADR, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens HM,. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 2005; 23: 225-234.
51. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD,. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006; 57: 427-435.
52. Gupta P, Friberg LE, Karlsson MO, Krishnaswami S, French J,. A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J Clin Pharmacol 2010; 50: 679-687.
53. Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JM, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Fety R, Van der Vijgh WJF, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM,. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 2007; 13: 6410-6418.
54. Quartino AL, Friberg LE, Karlsson MO,. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs 2012; 30: 833-845.
55. Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M,. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2012; 70: 591-601.
56. Quartino AL, Karlsson MO, Lindman H, Friberg LE,. An Integrated G-CSF-myelosuppression model characterizing the target mediated disposition of endogenous G-CSF in breast cancer patients following chemotherapy. Annual Meeting of the Population Approach Group in Europe (PAGE). June 7, 2011; Athens, Greece.
57. Agoram B, Heatherington AC, Gastonguay MR,. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 2006; 8: E552-563.
58. Fetterly GJ, Owen JS, Stuyckens K, Passarell JA, Zannikos P, Soto-Matos A, Izquierdo MA, Perez-Ruixo JJ,. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer Chemother Pharmacol 2008; 62: 135-147.
59. Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JHM, Karlsson MO, Huitema ADR,. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn 2010; 37: 347-363.
60. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO,. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002; 72: 265-275.
61. Henin E, You B, VanCutsem E, Hoff PM, Cassidy J, Twelves C, Zuideveld KP, Sirzen F, Dartois C, Freyer G, Tod M, Girard P,. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther 2009; 85: 418-425.
62. Holford NH,. A time to event tutorial for pharmacometricians. CPT: Pharmacometrics & Systems Pharmacology 2013; 2: e43.
63. Collett D,. Modelling Survival Data in Medical Research, second edn. Hall/CRC C, editors. Boca Raton, FL: CRC Press LLC, 2003.
64. Hooker AC, Karlsson M, editors. The Kaplan-Meier Mean Covariate plot (KMMC): a new diagnostic for covariates in time-to-event models. Annual Meeting of the Population Approach Group in Europe (PAGE). June 5, 2012; Venice, Italy.
65. Claret L, Lu JF, Sun YN, Bruno R,. Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. Cancer Chemother Pharmacol 2010; 66: 1141-1149.
66. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning Y, Arlen PM, Price D, Bates SE, Fojo T,. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011; 17: 907-917.
67. Bruno R, Jonsson F, Zaki M, Jacques C, Swern AS, Richardson PG, Rajkumar V, Claret L,. Simulation of clinical outcome for pomalidomide plus low-dose dexamethasone in patients with refractory multiple myeloma based on week 8 M-protein response. ASH Annual Meeting Abstracts. December 10, 2011: #1881.
68. Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schoffski P, Shah MH, Verweij J, Baum CM, Demetri GD,. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res 2009; 15: 5869-5877.
69. Gupta D, Lis CG,. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 2010; 9: 69. doi: 10.1186/1475-2891-9-69.
70. Bruno R, Olivares R, Berille J, Chaikin P, Vivier N, Hammershaimb L, Rhodes GR, Rigas JR,. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003; 9: 1077-1082.
71. Eskander RN, Tewari KS,. Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian, and cervical cancer: a systematic review. J Hematol Malignancies 2012; 2: 63-73.
72. Yang J, Zhao H, Garnett C, Rahman A, Gobburu JV, Pierce W, Schechter F, Summers J, Keegan P, Booth B, Wang Y,. The combination of exposure-response and case-control analyses in regulatory decision making. J Clin Pharmacol 2013; 53: 160-166.
73. Wallin JE, Friberg LE, Karlsson MO,. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol 2010; 106: 234-242.